Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12:30pm, Thursday, 21'st May 2020
Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 70,000 shares of Geron common stock as an inducement to a newly-hired emplo
Les sociétés pharmaceutiques Janssen de Johnson & Johnson ont annoncé aujourd'hui les résultats de l'étude CHRYSALIS de phase 1, qui évalue l'amiv
Why Geron Stock Soared 23.4% Today
05:24pm, Friday, 15'th May 2020
The bio pharmaceutical announced fresh data on imetelstat that it will present at a key conference next month.
Xconomy: From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq
02:12pm, Friday, 15'th May 2020
Legend Biotech, a cancer cell therapy developer with roots in China, is preparing for a US stock exchange listing as its lead candidate keeps pace in the
3 “Strong Buy” Penny Stocks With Triple-Digit Upside
06:22pm, Thursday, 14'th May 2020
Given the troubling state of the U.S. economy, what’s driving the bullish sentiment on Wall Street? Stimulus.Among the bulls is chief investment strategist at CFRA, Sam Stovall, who estimates that t
Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress
01:05pm, Thursday, 14'th May 2020
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data and analyses related to imetelstat, the Company’s
Geron Announces Four Imetelstat Presentations at the Virtual Edition of the European Hematology Association Annual Congress
12:00am, Thursday, 14'th May 2020
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four abstracts containing new clinical data an
5 Stem Cell Companies Racing Towards COVID-19 ARDS Therapy
04:35pm, Thursday, 07'th May 2020
Athersys and Mesoblast enroll first patients in Phase II/III placebo controlled COVID-19 ARDS trials. Capricor, Mesoblast and Pluristem make waves with very pro
What You Should Know About Alexion's $1.4B Proposed Buyout Of Portola Pharma
12:00am, Tuesday, 05'th May 2020
Large-cap biopharma Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced a deal Tuesday to buy its small-cap peer Portola Pharmaceuticals Inc (NASDAQ: PTLA). The news comes...
Les sociétés pharmaceutiques Janssen de Johnson & Johnson annoncent ce jour que le Comité des médicaments à usage humain (CHMP) de l'Agence europé
Attention Biotech Investors: Mark Your Calendar For These May PDUFA Dates
12:00am, Sunday, 03'rd May 2020
April turned out to be a productive month in terms of drug approvals, with the FDA issuing positive verdicts on almost all applications for which decisions were due. The month saw...
